Amakuru agezweho ya RD13-02 yo kuvura abarwayi ba R/R T-ALL/LBL mu kanwa

RD13-02 ni umuti w’uturemangingo twa CAR-T wibanda ku matsinda ya CD7 akomoka ku batanga serivisi nziza, kandi ugenewe kuvura kanseri y’amaraso ya T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) yasubiwemo cyangwa idashobora kugaragara. Yahinduwe mu buryo bw’uturemangingo kugira ngo hirindwe fratricide, indwara ya graft-versus-host (GvHD), na host-versus-graft reject (HvG) mu gihe yongera imbaraga zo kurwanya kanseri. RD13-02 ishobora gutegurwa mu itsinda rimwe ku bantu benshi, ikabasha kugera ku bushobozi "budasanzwe" ku barwayi bakeneye ubuvuzi bwa CAR-T cell.

Ku ya 7 Ugushyingo 2024, Bioheng Therapeutics yatangaje ko izagaragaza amakuru agezweho y’icyiciro cya mbere cy’umuti wayo wa CAR-T cell RD13-02, ugamije kuvura abarwayi ba T-ALL/LBL basubitse/barwaye indwara yo mu bwonko (R/R), mu kiganiro cyatanzwe mu nama ngarukamwaka ya 66 y’Umuryango w’Abanyamerika w’Ubuvuzi bw’Amazi (ASH). Iyi nama izaba kuva ku ya 7 kugeza ku ya 10 Ukuboza 2024, i San Diego, muri Amerika.

Ibisubizo: Ku ya 1 Kanama 2024, abantu 18 bujuje ibisabwa bafite R/R T-ALL/LBL biyandikishije (13 ALL, 5 LBL), bafite imyaka 33.5 (intera, 11 kugeza 67). Imirongo isanzwe y’ubuvuzi yari 2 (intera, 1 kugeza 5), ​​naho 4 bari bafite allo-HSCT mbere yo kwiyandikisha. Igipimo cy’impuzandengo cy’ibisasu bya BM cyari 71% (intera: 6% kugeza 90%) muri 18, aho 9 (6 ALL, 3 LBL) bagaragaje ko bafite ikibazo cyo hanze y’umugongo. Nta kintu na kimwe cyagaragaye ku burozi (DLT) cyangwa uburozi bw’ubwonko ku rugero rwose rw’umuti, aho habayeho ikibazo kimwe gusa cya Gr1 GvHD. Cytokine release syndrome (CRS) yashobotse, inyinshi muri zo zikaba zari zoroshye (Gr1, n=10; Gr2, n=5; Gr3, n=3). Ubwandu bw’ubwoko ubwo aribwo bwose bwabaye mu byiciro 13 (72%) (≥Gr3 mu byiciro 2 [11%)). Bitewe n’uko Gr3 CRS yagaragaye mu gice kimwe cya DL2 na DL3, abashakashatsi bashyizeho DL1 nk'igipimo cyo kongera, bibanda cyane ku mutekano n'ubushobozi. Mu gihe cyo kongera igipimo, igice kimwe cyapfuye azize indwara ya tumor lysis syndrome ku munsi wa 20 nyuma yo guterwa.

Mu isuzuma rya mbere ry’iminsi 28 nyuma yo guterwa, amanota 14 kuri 17 yapimwe yageze kuri CR/CRi. Mu gihe mu kwezi kwa kabiri nyuma yo guterwa, andi manota abiri yageze kuri CR/CRi, igipimo cya CR/CRi cya 94% (16/17). Mu manota afite CR/CRi, 100% yageze kuri minini residue disease (MRD) negative status binyuze mu isesengura rya flow cytometry. Igipimo cya Cmax cy’uturemangingo twa CAR-T mu maraso yo ku ruhande cyari kopi 1.863.601/μg ya ADN ya genomic (itandukaniro, kuva kuri 275.044 kugeza kuri 3.763.587) hakoreshejwe qPCR, igihe kirekire cyane kikaba cyararenze iminsi 90.

Umwanzuro: RD13-02, ibicuruzwa bya CAR-T bikoreshwa mu buryo bwa "bidakunze kuboneka", byagaragaje umutekano ugenzurwa kandi birushaho kugira akamaro mu kuvura R/R CD7 T-ALL/LBL. Ikigaragara ni uko 100% bya CR/CRipts byageze ku rwego rwo kudakira kwa MRD, bigatuma ubuvuzi bwihuse bwa pts.

Kuri ubu, hari andi magerageza menshi ya CAR-T mu Bushinwa, kandi barimo gushaka abarwayi. Kugira ngo ubone inama ku miti mishya n'ikoranabuhanga, ushobora kuvugana n'Ishami Mpuzamahanga ry'Ibitaro bya Oncology bya Beijing Region South.

Nimero ya Terefone: 4008803716

Email：myimmnet@163.com

Amareferensi

1.https://www.bioheng.com/News_Details/26.html

2.https://ash.confex.com/ash/2024/webprogram/Paper207322.html

3.http: //myimm.net/mianyizhiliao/2035.html